Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.07
HSIC's Cash to Debt is ranked lower than
92% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.61 vs. HSIC: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
HSIC' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.31 Max: 1.76
Current: 0.07
0.04
1.76
Equity to Asset 0.44
HSIC's Equity to Asset is ranked higher than
52% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.44 vs. HSIC: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
HSIC' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.51 Max: 0.67
Current: 0.44
0.42
0.67
Interest Coverage 26.02
HSIC's Interest Coverage is ranked higher than
63% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.09 vs. HSIC: 26.02 )
Ranked among companies with meaningful Interest Coverage only.
HSIC' s Interest Coverage Range Over the Past 10 Years
Min: 11.01  Med: 19.51 Max: 29.73
Current: 26.02
11.01
29.73
F-Score: 5
Z-Score: 4.93
M-Score: -2.52
WACC vs ROIC
9.28%
14.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 6.71
HSIC's Operating margin (%) is ranked higher than
69% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.78 vs. HSIC: 6.71 )
Ranked among companies with meaningful Operating margin (%) only.
HSIC' s Operating margin (%) Range Over the Past 10 Years
Min: 6.02  Med: 6.9 Max: 7.1
Current: 6.71
6.02
7.1
Net-margin (%) 4.40
HSIC's Net-margin (%) is ranked higher than
71% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.86 vs. HSIC: 4.40 )
Ranked among companies with meaningful Net-margin (%) only.
HSIC' s Net-margin (%) Range Over the Past 10 Years
Min: 3.24  Med: 4.34 Max: 4.76
Current: 4.4
3.24
4.76
ROE (%) 17.06
HSIC's ROE (%) is ranked higher than
85% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.93 vs. HSIC: 17.06 )
Ranked among companies with meaningful ROE (%) only.
HSIC' s ROE (%) Range Over the Past 10 Years
Min: 12.04  Med: 15.28 Max: 17.06
Current: 17.06
12.04
17.06
ROA (%) 7.60
HSIC's ROA (%) is ranked higher than
86% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.03 vs. HSIC: 7.60 )
Ranked among companies with meaningful ROA (%) only.
HSIC' s ROA (%) Range Over the Past 10 Years
Min: 5.99  Med: 7.74 Max: 8.37
Current: 7.6
5.99
8.37
ROC (Joel Greenblatt) (%) 42.33
HSIC's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.27 vs. HSIC: 42.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSIC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 41.4  Med: 48.65 Max: 51.27
Current: 42.33
41.4
51.27
Revenue Growth (3Y)(%) 8.30
HSIC's Revenue Growth (3Y)(%) is ranked higher than
56% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 7.80 vs. HSIC: 8.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSIC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.6  Med: 9.5 Max: 17.2
Current: 8.3
-12.6
17.2
EBITDA Growth (3Y)(%) 8.30
HSIC's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 38 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.80 vs. HSIC: 8.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSIC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.3  Med: 12.1 Max: 38.9
Current: 8.3
8.3
38.9
EPS Growth (3Y)(%) 9.60
HSIC's EPS Growth (3Y)(%) is ranked lower than
65% of the 37 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.30 vs. HSIC: 9.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HSIC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.2  Med: 12.1 Max: 70.7
Current: 9.6
6.2
70.7
GuruFocus has detected 1 Warning Sign with Henry Schein Inc $HSIC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HSIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HSIC Guru Trades in Q1 2016

Paul Tudor Jones 2,700 sh (New)
Jim Simons 41,006 sh (New)
Ken Fisher 499,512 sh (-0.50%)
Jeremy Grantham 146,858 sh (-2.97%)
Ron Baron 378,727 sh (-3.80%)
Mario Gabelli 170,292 sh (-6.94%)
» More
Q2 2016

HSIC Guru Trades in Q2 2016

Ray Dalio 2,300 sh (New)
Jim Simons 56,906 sh (+38.77%)
Paul Tudor Jones 3,600 sh (+33.33%)
Ron Baron 378,609 sh (-0.03%)
Ken Fisher 496,793 sh (-0.54%)
Mario Gabelli 162,772 sh (-4.42%)
Jeremy Grantham 69,783 sh (-52.48%)
» More
Q3 2016

HSIC Guru Trades in Q3 2016

Steven Cohen 132,300 sh (New)
Jim Simons Sold Out
Ray Dalio Sold Out
Ron Baron 378,009 sh (-0.16%)
Mario Gabelli 159,022 sh (-2.30%)
Ken Fisher 479,454 sh (-3.49%)
Paul Tudor Jones 2,200 sh (-38.89%)
Jeremy Grantham 13,354 sh (-80.86%)
» More
Q4 2016

HSIC Guru Trades in Q4 2016

Ken Fisher 462,101 sh (-3.62%)
» More
» Details

Insider Trades

Latest Guru Trades with HSIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution    NAICS: 423450    SIC: 5047
Compare:OTCPK:SHTDY, NYSE:ABC, NAS:PDCO, NYSE:PBH, NYSE:OMI, NYSE:PMC, NYSE:CAH, OTCPK:SNYR, OTCPK:FZMD, OTCPK:NPHC, OTCPK:SCVM, NYSE:MCK » details
Traded in other countries:HS2.Germany,
Henry Schein Inc is engaged in providing health care products and services to office-based dental, animal health and medical practitioners. It also provides its services to government, institutional health care clinics and other alternate care clinics.

Henry Schein Inc was incorporated in Delaware in December 1992. The Company is engaged in offering a selection of products and services and value-added solutions for operating efficient practices and delivering high quality care. The Company operates through a centralized and automated distribution network with a selection of more than 96,000 branded products and Henry Schein private brand products in stock, as well as more than 110,000 additional products available as special order items. It also offers its customers technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services. The Company conducts its business through two reportable segments: health care distribution and technology and value-added services. The health care distribution reportable segment aggregates its dental, animal health and medical operating segments. This segment consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Company's technology and value-added services group provides software, technology and other value-added services to health care practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. The Company's value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The Company's competitors include the GACD Group, Pluradent AG & Co., Lifco AB, Planmeca Oy, Billericay Dental Supply Co. Ltd., National Veterinary Services and Alcyon SA. The Company's business is subject to local, state, federal and foreign governmental laws and regulations applicable to the distribution of pharmaceuticals and medical devices. The Company's businesses are subject to various additional federal, state, local and foreign laws and regulations, including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially hazardous substances, and safe working conditions. Its businesses are also subject to requirements of similar and other foreign governmental laws and regulations affecting its operations abroad.

Guru Investment Theses on Henry Schein Inc

Baron Funds Comments on Henry Schein Inc. - Oct 21, 2016

Shares of Henry Schein, Inc. (NASDAQ:HSIC), a global distributor of dental, medical, and animal health products, declined after reporting an unexpected slowdown in its North American dental and equipment sales. No specific reasons for the slowdown have emerged, and we believe that it is too early to extrapolate a trend. While performance in other divisions was solid, Schein’s earnings guidance was revised downward for the first time in several years. We are monitoring events but remain positive given, in our opinion, the company’s strong management, consistent performance, and large market opportunities.





From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Henry Schein Inc

Baron Funds Comments on Henry Schein Inc. Guru stock highlight
Shares of Henry Schein, Inc. (NASDAQ:HSIC), a global distributor of dental, medical, and animal health products, declined after reporting an unexpected slowdown in its North American dental and equipment sales. No specific reasons for the slowdown have emerged, and we believe that it is too early to extrapolate a trend. While performance in other divisions was solid, Schein’s earnings guidance was revised downward for the first time in several years. We are monitoring events but remain positive given, in our opinion, the company’s strong management, consistent performance, and large market opportunities. Read more...
Don’t Buy a 'Valuation High' Even well-regarded sources can give bad advice. Trust the numbers.
Imagine you just had the best week ever. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.09
HSIC's P/E(ttm) is ranked lower than
66% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.19 vs. HSIC: 26.09 )
Ranked among companies with meaningful P/E(ttm) only.
HSIC' s P/E(ttm) Range Over the Past 10 Years
Min: 12.02  Med: 22.43 Max: 33.94
Current: 26.09
12.02
33.94
Forward P/E 21.88
HSIC's Forward P/E is ranked lower than
93% of the 14 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.05 vs. HSIC: 21.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.09
HSIC's PE(NRI) is ranked lower than
63% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.25 vs. HSIC: 26.09 )
Ranked among companies with meaningful PE(NRI) only.
HSIC' s PE(NRI) Range Over the Past 10 Years
Min: 12.02  Med: 21.9 Max: 30.67
Current: 26.09
12.02
30.67
Price/Owner Earnings (ttm) 26.44
HSIC's Price/Owner Earnings (ttm) is ranked lower than
68% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 17.33 vs. HSIC: 26.44 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HSIC' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.97  Med: 22.8 Max: 41.85
Current: 26.44
10.97
41.85
P/B 4.39
HSIC's P/B is ranked lower than
90% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.35 vs. HSIC: 4.39 )
Ranked among companies with meaningful P/B only.
HSIC' s P/B Range Over the Past 10 Years
Min: 1.57  Med: 3.05 Max: 5.02
Current: 4.39
1.57
5.02
P/S 1.16
HSIC's P/S is ranked lower than
52% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.11 vs. HSIC: 1.16 )
Ranked among companies with meaningful P/S only.
HSIC' s P/S Range Over the Past 10 Years
Min: 0.48  Med: 0.89 Max: 1.36
Current: 1.16
0.48
1.36
PFCF 22.26
HSIC's PFCF is ranked lower than
61% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.14 vs. HSIC: 22.26 )
Ranked among companies with meaningful PFCF only.
HSIC' s PFCF Range Over the Past 10 Years
Min: 9.3  Med: 19.39 Max: 34.25
Current: 22.26
9.3
34.25
POCF 20.04
HSIC's POCF is ranked lower than
71% of the 24 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.63 vs. HSIC: 20.04 )
Ranked among companies with meaningful POCF only.
HSIC' s POCF Range Over the Past 10 Years
Min: 8.08  Med: 16.35 Max: 28.67
Current: 20.04
8.08
28.67
EV-to-EBIT 17.04
HSIC's EV-to-EBIT is ranked lower than
56% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.14 vs. HSIC: 17.04 )
Ranked among companies with meaningful EV-to-EBIT only.
HSIC' s EV-to-EBIT Range Over the Past 10 Years
Min: 6  Med: 12.4 Max: 20.7
Current: 17.04
6
20.7
EV-to-EBITDA 14.02
HSIC's EV-to-EBITDA is ranked lower than
63% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.83 vs. HSIC: 14.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSIC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.2  Med: 10.6 Max: 17
Current: 14.02
5.2
17
PEG 2.73
HSIC's PEG is ranked lower than
60% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.14 vs. HSIC: 2.73 )
Ranked among companies with meaningful PEG only.
HSIC' s PEG Range Over the Past 10 Years
Min: 0.56  Med: 2.1 Max: 3.33
Current: 2.73
0.56
3.33
Shiller P/E 35.85
HSIC's Shiller P/E is ranked lower than
61% of the 18 Companies
in the Global Medical Distribution industry.

( Industry Median: 29.09 vs. HSIC: 35.85 )
Ranked among companies with meaningful Shiller P/E only.
HSIC' s Shiller P/E Range Over the Past 10 Years
Min: 20.75  Med: 33.63 Max: 49.34
Current: 35.85
20.75
49.34
Current Ratio 1.61
HSIC's Current Ratio is ranked lower than
51% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.65 vs. HSIC: 1.61 )
Ranked among companies with meaningful Current Ratio only.
HSIC' s Current Ratio Range Over the Past 10 Years
Min: 1.5  Med: 2.13 Max: 2.78
Current: 1.61
1.5
2.78
Quick Ratio 0.89
HSIC's Quick Ratio is ranked lower than
67% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.13 vs. HSIC: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
HSIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.36 Max: 1.77
Current: 0.89
0.8
1.77
Days Inventory 66.32
HSIC's Days Inventory is ranked lower than
65% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 42.01 vs. HSIC: 66.32 )
Ranked among companies with meaningful Days Inventory only.
HSIC' s Days Inventory Range Over the Past 10 Years
Min: 54.28  Med: 58.07 Max: 67.99
Current: 66.32
54.28
67.99
Days Sales Outstanding 44.17
HSIC's Days Sales Outstanding is ranked higher than
62% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 61.85 vs. HSIC: 44.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.01  Med: 41.72 Max: 44.17
Current: 44.17
38.01
44.17
Days Payable 41.80
HSIC's Days Payable is ranked lower than
74% of the 38 Companies
in the Global Medical Distribution industry.

( Industry Median: 65.77 vs. HSIC: 41.80 )
Ranked among companies with meaningful Days Payable only.
HSIC' s Days Payable Range Over the Past 10 Years
Min: 37.11  Med: 42.2 Max: 48.19
Current: 41.8
37.11
48.19

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.10
HSIC's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 33 Companies
in the Global Medical Distribution industry.

( Industry Median: -1.10 vs. HSIC: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSIC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.4  Med: -0.8 Max: 2.3
Current: 2.1
-22.4
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 38.95
HSIC's Price/Tangible Book is ranked lower than
100% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.51 vs. HSIC: 38.95 )
Ranked among companies with meaningful Price/Tangible Book only.
HSIC' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.37  Med: 7.53 Max: 42.4
Current: 38.95
2.37
42.4
Price/Projected FCF 1.49
HSIC's Price/Projected FCF is ranked lower than
52% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.49 vs. HSIC: 1.49 )
Ranked among companies with meaningful Price/Projected FCF only.
HSIC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.39 Max: 22.69
Current: 1.49
0.78
22.69
Price/DCF (Earnings Based) 1.51
HSIC's Price/DCF (Earnings Based) is ranked lower than
56% of the 9 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.41 vs. HSIC: 1.51 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.30
HSIC's Price/Median PS Value is ranked lower than
71% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.00 vs. HSIC: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
HSIC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 0.89 Max: 1.49
Current: 1.3
0.27
1.49
Price/Peter Lynch Fair Value 2.93
HSIC's Price/Peter Lynch Fair Value is ranked lower than
87% of the 15 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.63 vs. HSIC: 2.93 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
HSIC' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.59  Med: 1.7 Max: 3.26
Current: 2.93
0.59
3.26
Price/Graham Number 6.74
HSIC's Price/Graham Number is ranked lower than
97% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.77 vs. HSIC: 6.74 )
Ranked among companies with meaningful Price/Graham Number only.
HSIC' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 2.95 Max: 23.53
Current: 6.74
1.09
23.53
Earnings Yield (Greenblatt) (%) 5.87
HSIC's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.70 vs. HSIC: 5.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSIC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.8  Med: 8.1 Max: 16.7
Current: 5.87
4.8
16.7
Forward Rate of Return (Yacktman) (%) 12.59
HSIC's Forward Rate of Return (Yacktman) (%) is ranked higher than
56% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.17 vs. HSIC: 12.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSIC' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 10.4  Med: 15 Max: 28.6
Current: 12.59
10.4
28.6

More Statistics

Revenue (TTM) (Mil) $11,302
EPS (TTM) $ 6.01
Beta0.98
Short Percentage of Float4.00%
52-Week Range $142.72 - 183.00
Shares Outstanding (Mil)80.49

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 11,492 12,143 12,842 13,146
EPS ($) 6.58 7.26 8.11 9.25
EPS w/o NRI ($) 6.58 7.26 8.11 9.25
EPS Growth Rate
(3Y to 5Y Estimate)
13.12%
Dividends Per Share ($)
» More Articles for HSIC

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Henry Schein Inc. Oct 21 2016 
Companies Trading with Low Price-Sales Ratios Aug 18 2016 
Don’t Buy a 'Valuation High' Jun 18 2016 
The Best Companies of the Medical Industry – September 2015 Sep 25 2015 
The Case for Investing in AmerisourceBergen Aug 13 2015 
Weekly 52-Week Highs Highlight: BCS, RYAAY, MMC, HSIC Jun 14 2015 
Why Hedge Funds Are Betting On AmerisourceBergen Apr 10 2015 
Weekly 52-Week Highs Highlight: DLTR, NTES, HSIC, ADM Nov 23 2014 
AmerisourceBergen Is a Center Piece in the Pharma Industry Sep 30 2014 
Weekly 52-Week Highs Highlight: IHG, HSIC, GGP, AAL Jun 02 2014 

More From Other Websites
Henry Schein Completes Acquisition Of A Majority Interest In Dental Cremer Jan 17 2017
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers Jan 12 2017
Henry Schein upgraded by Gabelli & Co Jan 10 2017
Jim Cramer's Top Takeaways: VCA, Johnson Controls, Adient Jan 10 2017
Henry Schein, Inc. breached its 50 day moving average in a Bullish Manner : HSIC-US : December 28,... Dec 28 2016
Henry Schein Named 2016's Best Animal Healthcare Provider Dec 22 2016
Henry Schein Named 'Best Animal Healthcare Product Provider 2016' By Global Health & Pharma Dec 20 2016
Henry Schein Named 'Best Animal Healthcare Product Provider 2016' By Global Health & Pharma Dec 20 2016
Henry Schein, Inc. – Value Analysis (NASDAQ:HSIC) : December 19, 2016 Dec 19 2016
Henry Schein To Present At The 35th Annual J.P. Morgan Healthcare Conference Dec 19 2016
Henry Schein, Inc. breached its 50 day moving average in a Bullish Manner : HSIC-US : December 16,... Dec 16 2016
Henry Schein's 18th Annual Holiday Cheer For Children Spreads Joy To Children And Their Families... Dec 13 2016
Henry Schein Buys Stake in Marrodent; Spurs Polish Foothold Dec 09 2016
Milestone Scientific, Inc. Reports Progress Related to its Exclusive Distribution Agreement with... Dec 08 2016
Henry Schein's Q3 Results Impress, Pricing Pressure a Drag Dec 08 2016
Henry Schein Completes Investment With Full-Service Dental Distributor Marrodent Dec 08 2016
Microchip Technology Inc. (MCHP): What Smart Money Thinks about This Stock? Dec 07 2016
Institutional Investor Recognizes Henry Schein Management Team In All-America Executive Team Surveys Dec 07 2016
Veterinary supplier plans to add 50 jobs in Columbus, Dublin Dec 05 2016
Henry Schein Earns Top Marks In 2017 Corporate Equality Index Dec 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)